healthprofessionalradio, Author at Health Professional Radio

Digitech Systems’ Success Stories [Interview][Transcript]

23 June 2017

No comments

Guest: Sean Morris

Presenter: Neal Howard

Guest Bio: Mr. Sean Morris has more than eleven years experience in the ECM market. Serving as Digitech Systems’ Director of Sales, Sean is focused on developing and strengthening channel selling systems and reseller strategies. He is responsible for managing Digitech Systems’ reseller base, industry forecasting, driving revenue, and supporting the management of marketing and public relations.

Segment overview: Sean Morris, Director of Sales for Digitech Systems is back to talk about three success stories made possible with Digitech’s ECM software and services.

The Opioid Epidemic [Interview][Transcript]

23 June 2017

No comments

Guest: Dr. Keri Donaldson

Presenter: Neal Howard

Guest Bio: Dr. Keri Donaldson’s work as Medical Director and CEO of Prescient Medicine is fueled by an extensive background in the fields of pathology, genomics, and diagnostics. An active ad hoc reviewer and consultant, Dr. Donaldson has earned a reputation as an innovative member of the medical community and garnered key positions within respected institutions and national committees. He was certified as a diplomate of both the American Board of Pathology and the National Board of Medical Examiners, and holds a BS from Pennsylvania State University, an MD from Temple University School of Medicine, and a master of science in clinical epidemiology (MSCE) from the University of Pennsylvania School of Medicine.

Segment overview: Dr. Keri Donaldson, CEO of Prescient Medicine, talks about the Opioid Epidemic and the FDA’s recent request that a painkiller be pulled from the market by its manufacturer. Also discussed is the first Annual “Solving The Opioid Crisis” Summit.

Treatment Options for Schizophrenia [Interview][Transcript]

23 June 2017

No comments

Guest: Dr. Joe McEvoy

Presenter: Neal Howard

Guest Bio: Dr. McEvoy is a distinguished, tenured professor of psychiatry and health behaviors at Augusta University. He also serves as the I. Clark Case chair in psychotic disorders and as the director of public psychiatry in Augusta University’s partnership with the Georgia Department of Behavioral Health and Developmental Disabilities (DBHDD). His research and clinical work have focused on severe and persistent mental disorders (primarily schizophrenia, schizoaffective disorder, and bipolar disorder). He is currently the principal investigator for the NIMH-funded ACLAIMS (A Comparison of Long-Acting Injected Medications for Schizophrenia) trial.

Segment overview: Dr. Joe McEvoy, professor of psychiatry and health behaviors at Augusta University talks about the review data published in AJP (American Journal of Psychiatry) and the growing body of research that is reshaping the way we look at treatment options for people with schizophrenia.

Schizophrenia’s Unique Patient Challenges [Interview][Transcript]

23 June 2017

No comments

Guest: Dr. Joe McEvoy

Presenter: Neal Howard

Guest Bio: Dr. McEvoy is a distinguished, tenured professor of psychiatry and health behaviors at Augusta University. He also serves as the I. Clark Case chair in psychotic disorders and as the director of public psychiatry in Augusta University’s partnership with the Georgia Department of Behavioral Health and Developmental Disabilities (DBHDD). His research and clinical work have focused on severe and persistent mental disorders (primarily schizophrenia, schizoaffective disorder, and bipolar disorder). He is currently the principal investigator for the NIMH-funded ACLAIMS (A Comparison of Long-Acting Injected Medications for Schizophrenia) trial.

Segment overview: Dr. Joe McEvoy, professor of psychiatry and health behaviors at Augusta University discusses the current schizophrenia landscape, recent FDA approvals, and real world experience in how his patients face unique challenges as a result of their disease.

The Health News – 23 June 2017

23 June 2017

No comments

Parents of children with special needs have reacted strongly to Pauline Hanson’s controversial calls for them to be removed from mainstream classrooms, with many calling the comments “offensive”. They argue that rather than disadvantaging their classmates by monopolising teachers’ time, children with special needs actually enrich the learning environment.
Public hospitals that deliver 73 per cent of Australia’s babies are so overstretched more than a third of women can’t get an antenatal appointment in the first 14 weeks of their pregnancy. And fewer than one in ten women are getting access to continuity of care with the same doctor or team of midwives.
People can now find out if their genetics and lifestyle has left them prone to developing a suite of life-threatening conditions including 31 types of cancer and 13 heart conditions across 230 genes.
Launched on Tuesday by Sydney’s Garvan Institute’s Genome.One lab and corporate clinic Life First, the service also offers individuals the ability to predict how they would likely react to more than 220 medications, allowing clinicians to better tailor treatment to their patients.

Australia’s Unifying Voice with Governments and the Community on all Matters Concerning Medical Cannabis [Interview][Transcript]

20 June 2017

No comments

Guest: Adam Miller

Presenter: Henry Acosta

Guest Bio: Founder of BuddingTech and The Medical Cannabis Council, Adam completed his studies of Business Entrepreneurship at Royal Melbourne Institute of Technology and Sweden’s Jönköping University for international business in 2009. In 2016 Adam published two Australian industry White Papers with MGC Pharmaceuticals & The University of Sydney on medical cannabis. Additionally, Adam is the organiser of Seedlings, Australia first medical cannabis innovation conference.

Segment overview: In today’s Health Supplier Segment, we welcome Adam Miller here to discuss the launching of The Medical Cannabis Council this week in Melbourne. The Council will be the peak industry body that aims to develop best practice and standards for producing, supplying and distributing medical cannabis products. The founding members are industry leaders and experts in the fields of health and medical cannabis, including CEO of Epilepsy Action Australia, Carol Ireland; Director of Neurology at St. Vincent’s hospital in Melbourne, Professor Mark Cook; and preventative health expert and cardiologist, Dr Ross Walker. The Council will position Australia as a world leader in research and the production of safe, scientifically-backed, medical cannabis products. The launch comes during Medical Cannabis Awareness Week.

The Health News – 19 June 2017

20 June 2017

No comments

Overview:

• Each year about 149 children die and 680,000 children aged 16 and younger are hospitalised from injuries. Falls from playground equipment – which account for about a third of all hospitalisation – led to over 55,000 children hospitalised over the 10 years between 2002-2012. The 10-year study was published by Injury Prevention. It is the first time that injuries have been ranked. Previously non-fatal rankings didn’t exist, said academics.

• Australian food businesses say new country of origin labelling laws, which require them to redesign packaging, will cost tens of millions of dollars. Government-commissioned research found consumers really cared about where less processed products such as seafood, tinned tomatoes and honey came from, so the Government came up with labels that tell shoppers how much of a product is made, packed or processed in Australia.

• The release of the long awaited Australian Law Reform Commission (ALRC) report into elder abuse is a substantial step forward in addressing physical, sexual, psychological, emotional and financial abuse of the elderly. A total of 14 out of the ALRC’s forty three recommendations are about improving aged care, in both residential settings and the home.

The Health News – 16 June 2017

20 June 2017

No comments

Overview:

• Coca-Cola is dumping its popular Coke Zero soft drink and replacing it with its new product — Coca-Cola No Sugar . It will more closely mimic the flavour of Coca-Cola Classic, while still keeping the calories down. To support the launch, the company will hand out two million free samples of the new drink from mid-June until August and will back this up with a multimillion-dollar advertising campaign.

• The number of working-age Australians receiving the Disability Support Pension for mental health issues increased by about 50 per cent over a 13-year period, even though prevalence of the conditions remained stable. Researchers led by associate professor Samuel Harvey from the Black Dog Institute and the University of NSW reported their findings … in the Medical Journal of Australia. The researchers dismissed the “common belief that we are in the midst of a mental health epidemic” but warned that the impact of psychiatric conditions on work, society and the economy was significant, and still not fully understood.

• A new snapshot by the Society of Hospital Pharmacists of Australia (SHPA) from 280 metropolitan, regional and rural health service facilities found drug shortages were common. SHPA Professor Michael Dooley said more than 30 per cent of medication shortages had a direct impact on patient care. Pharmacists said they were concerned manufacturers were not alerting health authorities about shortages.

Medical Alert Bracelets for You and your Loved Ones’ Peace of Mind [Interview][Transcript]

16 June 2017

No comments

Guest: Michael Randall
Presenter: Henry Acosta
Guest Bio: Michael Randall is the CEO, Mediband since January 2004. During this time he launched several successful medical and health business units including TGA medical devices. His prior work includes roles in teaching international marketing & business; land and property management; and international business management.
As Mediband CEO he launched MedibandPlus, FeverMates medical device range and MediBC and oversaw expansion of Mediband to the USA, UK, South Africa, New Zealand amongst other countries. He lectured in International Marketing & business at the University of Technology, Sydney, July 1999 – December 2000; Chief Operating Officer at Frome Street Group of Companies; January 1990 – June 2003.

Segment overview: Mediband provides ready-to-wear and custom engraved identification alert bracelets in various styles – our signature product is the silicone based medical ID. MedibandPlus is an additional and optional emergency medical information service providing 24hr-accessible web-based medical information to medical personnel and first responders in emergencies. Mediband medical alert bracelets provide peace of mind so that when the unexpected happens, critical medical information can be conveyed to emergency personnel. These are helpful in making sure incorrect diagnosis and treatment is preveted, raising awareness of medical conditions such as allergies, and providing vital medical and contact information in emergencies.
Mediband® bracelets can be linked to the MedibandPlus web-based medical database enabling subscribers to store medical information for emergency access. The wristbands are available in a range of colours and sizes. They are also designed to break when enough force is applied to prevent snagging or catching injuries. MediBC provides access to a large range of first aid kits by St John and Trafalgar in addition to St John first aid training courses. Fevermates are a convenient, easy-to-read, fuss free stick-on fever & temperature indicators that allow you to continuously monitor your children’s fever or temperature for up to 48 hours at a glance.

Developing Technology which Allows the Mass Production of Stem Cells

16 June 2017

No comments

Guest: Dr. Ross Macdonald

Presenter: Henry Acosta

Guest Bio: Doctor Ross Macdonald is the CEO of Cynata Therapeutics, an Australian clinical stage regenerative medicine company that is developing a therapeutic stem cell technology called Cymerus, that allows for the mass production of stem cells. They recently began a world-first Phase I clinical trial into the effectiveness of their technology in treating patients with acute steroid-resistant graft-versus-host disease.

Segment overview: In today’s Health Supplier Segment, we are joined by the CEO of Cynata Therapeutics Dr. Ross Macdonald here to share update about their Cymerus™ technology to treat patients with steroid-resistant acute graft versus host disease (GvHD). The Cymerus platform allows for the mass-production of mesenchymal stem cells (MSCs) of a uniformly high quality using cells derived from a single blood donation. The first product currently being tested with the first patient treated a short time ago in the UK is called CYP-001, intended for the treatment of GvHD. Dr Ross hopes to one day increase the effective treatment options available to patients with life-threatening conditions such as acute steroid-resistant GvHD. According to him, if this present clinical trial is successful it will open up the door to many other potential therapeutic uses for Cynata’s unique Cymerus MSC technology. MSCs are currently being studied in over 650 clinical trials and Cynata itself already has strong data in pre-clinical models of heart attack and asthma, as well as other diseases, creating a very promising commercial opportunity for the company.